Surgical decision-making after neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma Authors: Huisong Lee Published: 2025 INTRODUCTION Neoadjuvant chemotherapy, once used mainly for borderline resectable pancreatic ductal adenocarcinoma (PDAC) to increase R0 resection rates and identify aggressive disease, is now increasingly applied even in resectable tumors [12]. This shift is supported by studies demonstrating the benefits of systemic therapy before surgery, including the prospective trial by Cecchini et al. [3] showing the value of neoadjuvant modified FOLFIRINOX in resectable PDAC. As neoadjuvant therapy becomes more common, determining when, how, and for whom surgery should be performed has become a central yet unresolved clinical challenge. Reliable tools are needed to assess treatment response and guide surgical decision-making. MAIN BODY Limitations of imaging-based response assessment CT and MRI remain the standard modalities for evaluating treatment response after neoadjuvant therapy, using RECIST (Response Evaluation Criteria in Solid Tumors) criteria and assessments of vascular involvement [4]. However, their accuracy is limited. Dense stromal reaction and treatment-induced fibrosis often mimic residual tumor, causing underestimation of true response. In many cases where imaging suggests persistent arterial or venous involvement, pathology reveals no actual vascular invasion [5]. Contrast-Enhanced Harmonic Endoscopic Ultrasonography may improve the assessment of vascular invasion [6], but it is not yet widely adopted. These limitations highlight the need for more biologically sensitive biomarkers to guide post-neoadjuvant surgical decisions. Serum CA19-9 and circulating tumor DNA CA19-9 remains a widely used and accessible biomarker in PDAC. Increasing attention has been given to CA19-9 kinetics during neoadjuvant therapy as predictors of outcome [7]. Chae et al. [8] reported that a ≥70% reduction in CA19-9 after chemotherapy correlates strongly with improved recurrence-free and overall survival. Because CA19-9 testing is simple, inexpensive, and reproducible, it is well suited for integration into routine surgical decision-making. Circulating tumor DNA (ctDNA) has emerged as a sensitive liquid biopsy tool capable of detecting minimal residual disease and monitoring treatment response [9]. Cecchini et al. [3] found that postoperative ctDNA negativity is associated with significantly better survival compared with ctDNA-positive patients. Lapin et al. [10] further showed that serial ctDNA monitoring in advanced PDAC reflects prognosis and treatment response. These findings suggest that ctDNA may help identify true responders to neoadjuvant therapy, even when imaging results remain equivocal. Recent work has explored combining CA19-9 and ctDNA for improved patient stratification. In the PANACHE01-PRODIGE48 trial, Pinson et al. [11] categorized patients by biomarker status and demonstrated clear survival differences among groups: worst outcomes in those with both elevated CA19-9 and ctDNA positivity, intermediate outcomes with either abnormal marker, and the best outcomes in those negative for both. This supports a combined biomarker approach for selecting surgical candidates after neoadjuvant therapy. The role of multidisciplinary decision-making Despite advances in biomarkers, surgical decision-making must still rely heavily on clinical judgment. Factors such as performance status, comorbidities, nutritional condition, and patient preference remain essential considerations. Multidisciplinary tumor boards—bringing together specialists in surgical, medical, and radiation oncology, radiology, gastroenterology, and pathology—play a key role in integrating imaging findings, biomarker results, and overall patient status [2]. This coordinated approach is particularly important in locally advanced PDAC, where the role of arterial resection remains controversial and high-quality evidence is lacking. As more effective systemic regimens, including mFOLFIRINOX and gemcitabine/nab-paclitaxel, have increased the frequency of conversion surgery in initially unresectable disease [12], careful evaluation is required to determine which patients truly benefit and what extent of surgery is appropriate. Biomarkers such as ctDNA and CA19-9 may help identify patients with favorable tumor biology who are most likely to benefit from aggressive surgical strategies. Ultimately, treatment decisions should be made within a multidisciplinary framework that integrates these diverse clinical and biological factors. CONCLUSION As neoadjuvant chemotherapy becomes increasingly integrated into the management of PDAC, refining criteria for post-treatment surgical decision-making is essential. Imaging alone is insufficient, while biomarkers such as CA19-9 decline and ctDNA clearance show promise as objective indicators of response. Their combined use may form the basis of future decision algorithms. Ultimately, surgical candidacy must be determined through a multidisciplinary approach that incorporates imaging, biomarkers, and clinical factors. Continued research is needed to establish validated frameworks that safely expand the benefits of neoadjuvant therapy and surgery in PDAC.